Kanjinti vs. Tukysa: Comparison
Are Kanjinti and Tukysa the Same Thing?
Kanjinti (trastuzumab-anns) and Tukysa (tucatinib) are used to treat HER2-positive breast cancer.
Kanjinti is also used to treat HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.
Tukysa is used in combination with trastuzumab and capecitabine to treat adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting.
Kanjinti is a HER2/neu receptor antagonist and Tukysa is a kinase inhibitor.
Side effects of Kanjinti and Tukysa that are similar include headache, diarrhea, nausea, rash, fatigue, anemia, and inflammation of the mouth and lips.
Side effects of Kanjinti that are different from Tukysa include chills, fever, infection, congestive heart failure, insomnia, cough, low white blood cell count (neutropenia), weight loss, upper respiratory tract infections, low blood platelets (thrombocytopenia), mucosal inflammation, runny or stuffy nose, and changes in taste.
Side effects of Tukysa that are different from Kanjinti include hand-foot syndrome (palmar-plantar erythrodysesthesia), liver toxicity, vomiting, decreased appetite, and abdominal pain.
Kanjinti may interact with anthracycline.
Tukysa may also interact with strong CYP3A inducers or moderate CYP2C8 inducers, strong or moderate CYP2C8 inhibitors, CYP3A substrates, and P-gp substrates.
What Are Possible Side Effects of Kanjinti?
Side effects of Kanjinti include:
- headache,
- diarrhea,
- nausea,
- chills,
- fever,
- infection,
- congestive heart failure,
- insomnia,
- cough,
- rash,
- low white blood cell count (neutropenia),
- fatigue,
- anemia,
- inflammation of the mouth and lips,
- weight loss,
- upper respiratory tract infections,
- low blood platelets (thrombocytopenia),
- mucosal inflammation,
- runny or stuffy nose,
- changes in taste
This is not a complete list of side effects, and others may occur.
What Are Possible Side Effects of Tukysa?
Common side effects of Tukysa include:
- diarrhea,
- hand-foot syndrome (palmar-plantar erythrodysesthesia),
- nausea,
- fatigue,
- liver toxicity,
- inflammation of mouth and lips,
- vomiting,
- decreased appetite,
- abdominal pain,
- headache,
- anemia, and
- rash
What is Kanjinti?
Kanjinti (trastuzumab-anns) is a HER2/neu receptor antagonist indicated for the treatment of HER2 overexpressing breast cancer and the treatment of HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.
What is Tukysa?
Tukysa (tucatinib) is a kinase inhibitor used in combination with trastuzumab and capecitabine to treat adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting.
What Drugs Interact With Kanjinti?
Kanjinti may interact with anthracycline. Tell your doctor all medications and supplements you use. Kanjinti is not recommended for use during pregnancy; it may harm a fetus. Females of reproductive potential are advised to use effective contraception during treatment with Kanjinti and for 7 months following the last dose. It is unknown if Kanjinti passes into breast milk or how it would affect a nursing infant. Consult your doctor before breastfeeding.
What Drugs Interact With Tukysa?
Tukysa may interact with other medicines such as:
- strong CYP3A inducers or moderate CYP2C8 inducers,
- strong or moderate CYP2C8 inhibitors,
- CYP3A substrates, and
- P-gp substrates
Tell your doctor all medications and supplements you use.
How Should Kanjinti be Taken?
The dose and regimen of Kanjinti depends on the condition being treated.
How Should Tukysa be Taken?
The recommended dosage of Tukysa is 300 mg taken orally twice daily with or without food.